Physician profile
Anu Khatri
NPI 1760406235
$56,018.63
in general payments reported to CMS, 2019-2025
26 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $693 · 2021: $22K · 2022: $18K · 2023: $8,364 · 2024: $5,135 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,938 · Food and Beverage: $4,367 · Travel and Lodging: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,937.50 |
| Food and Beverage | $4,366.80 |
| Travel and Lodging | $566.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,821.70 | 2021-2025 | |
| Allergan, INC. | $1,309.68 | 2020-2021 | |
| Lilly USA, LLC | $1,104.42 | 2019-2025 | Emgality, Mounjaro, Reyvow |
| Teva Pharmaceuticals USA, INC. | $948.82 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $840.09 | 2023-2025 | |
| Ucb, INC. | $702.83 | 2019-2024 | Briviact |
| Amgen INC. | $412.99 | 2019-2024 | Aimovig |
| Supernus Pharmaceuticals, INC. | $325.45 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $190.57 | 2021-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $184.69 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.81 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.55 | 2023-2025 | Caplyta |
| Ge Healthcare | $108.39 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $105.81 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $88.06 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.86 | 2020-2021 | |
| Acorda Therapeutics, INC | $81.78 | 2019 | |
| Novo Nordisk INC | $80.80 | 2022-2025 | |
| Axsome Therapeutics, INC. | $80.62 | 2025 | Symbravo |
| Emd Serono, INC. | $76.76 | 2023-2025 | Mavenclad |
| Eisai INC. | $55.85 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $38.88 | 2024-2025 | Airsupra |
| Neurocrine Biosciences, INC. | $36.90 | 2019 | |
| Neurelis, INC. | $26.40 | 2024 | Valtoco |
| Tonix Medicines, INC. | $19.27 | 2025 | Zembrace Symtouch |
| Kyowa Kirin, INC. | $18.65 | 2023 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Khatri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.